Novartis to cut Swiss, U.K. jobs to adapt manufacturing

Novartis AG (NYSE:NVS; SIX:NOVN) revealed restructuring plans that could remove a net of up to 1,700 Swiss-based jobs over four years as the pharma continues to evolve its business services organization and manufacturing strategy, spokesperson Eric Althoff told BioCentury.

Novartis plans a net reduction of about 1,000 positions across its Swiss manufacturing units, offset by its new Cell & Gene Therapy manufacturing unit in Stein, Switzerland, that could add up to 450 new positions, Althoff said...